Comparison of CYFRA 21-1, TPA and TPS in XXXX , @entity150 and benign diseases.

@entity1 @entity4166 @entity4153 @entity5 @entity957 @entity1149 @entity2 @entity150 @entity358 @entity152 @entity865 @entity151 @entity420
Recently CYFRA 21-1, a new @entity5 marker measuring a fragment of @entity4166 , was introduced and proved to be suitable for therapy monitoring and follow-up of @entity1149 ( @entity1149 ), in @entity957 . Besides CYFRA 21-1 there are two other @entity5 markers, tissue polypeptide antigen (TPA) and tissue polypeptide-specific antigen (TPS), which also measure various cytokeratins in serum. In a retrospective study we investigated the clinical significance of these three cytokeratin markers in @entity2 and in @entity150 . For this purpose we investigated the sera of 50 healthy @entity1 , 273 @entity1 with various benign diseases, 218 @entity1 with histologically proven @entity2 and 88 @entity1 with @entity150 . In a first step the specificity was established for the different reference groups and the cutoff values were fixed at a specificity of 95%. In @entity2 the single and combined sensitivities were calculated versus benign @entity358 (n = 58) as reference group. With single determinations CYFRA 21-1 proved to have the highest sensitivity in @entity2 in general (61%), in @entity1149 (64%), in @entity957 (79%), in @entity420 (54%) and in @entity152 (65%). In @entity151 ( @entity151 ) NSE was confirmed to be the marker of choice (55%). With combined determinations a clear increase in sensitivity could only be reached in @entity152 (CYFRA 21-1 + @entity865 : 77%) and in @entity4153 (CYFRA 21-1 + NSE: 62%).(ABSTRACT TRUNCATED AT 250 WORDS)
